FDA scolds SPL in manufacturing warning

The FDA has issued a warning letter to Scientific Protein Laboratories, one of the companies at the center of the heparin scandal in 2008, raising several questions about its handling of the drug. Report

Suggested Articles

Novartis is rolling out positive interim phase 3 data on Zolgensma in Europe, which could support the recent launch of the SMA gene therapy there.

The new cost-cutting goal comes on top of a €2.6 billion annual savings target the company already laid out in a revamp initiated in 2018.

As hearings continued on Capitol Hill, a congressional committee said Novartis, Amgen and Mallinckrodt used routine price hikes to meet sales targets.